| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | 0.074 | 0.03 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.03 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.099 | 0.03 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.03 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.03 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.04 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.04 |
| mRNA | XMD8-85 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.04 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | -0.071 | 0.04 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.076 | 0.04 |